Can exercise replace meds? study tests supervised vs. solo workouts for diabetes
NCT ID NCT06598865
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether supervised exercise classes or doing physical activity on your own works better for controlling blood sugar in adults with type 2 diabetes. About 120 people whose diabetes is not well controlled with diet or non-insulin medications will take part. Participants will either follow a 3-month exercise program with a trainer or exercise on their own, and their blood sugar levels will be tracked continuously for 10 days at the end of the study.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 120 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Feb 2025
- Expected to finish
-
Jun 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 67 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patient who has given consent to participate in the study and has signed an informed consent form. * Patient aged 18 to 67 years * Patient diagnosed with type 2 diabetes * Patient newly diagnosed or on non-insulin treatment (metformin +/- DPP4 inhibitor, GLP1 analogue +/- SGLT2 inhibitor) for whom it is considered to initiate or intensify antidiabetic treatment by introducing a new therapeutic class. * Patient insufficiently controlled (\> 1.30 g/L fasting blood glucose measured in the laboratory twice a few days apart in a city laboratory) * Patient with good venous access. * Patient capable of engaging in regular physical activity * Patient who has undergone a coronary artery disease screening test in the year prior to inclusion according to the new recommendations of an expert consensus. * Patient agrees to wear a FitBit Charge 6 bracelet for the entire duration of the study, including the run-in period, and agrees to recharge it and transmit the data. Exclusion Criteria: * Patient diagnosed with type 1 diabetes * Patient treated with sulfonylureas * Patient with a history of severe cardiovascular diseases (myocardial infarction, acute coronary syndrome, or stroke in the past year) * Patient presenting a medical contraindication to performing a physical activity session (uncontrolled resting hypertension, i.e., systolic blood pressure \> 160 mmHg and/or diastolic blood pressure \> 100 mmHg, unstable coronary artery disease, heart failure, severe proliferative or non-proliferative evolving retinopathy (unstabilized), or having undergone recent surgical laser treatment of the eye, plantar perforating ulcer, disabling osteoarthritis of the lower limbs, respiratory failure, severe renal impairment, liver failure, severe dysautonomia, i.e., risk of chronotropic insufficiency during exercise, peripheral neuropathy) * Patient with a history of severe hypoglycemia in the 6 months prior to entering the study and/or not feeling their hypoglycemia at all * Patient with an IPAQ score in the high category * Patient with a known latex allergy * Patient with morbid obesity (BMI \> 40 kg/m²) * Other conditions that may interfere with glycemic variation: particularly the use of corticosteroids during the study * Patient treated with beta-blockers or calcium channel blockers with negative chronotropic action (such as isoptin) * Breastfeeding woman * Pregnant woman\* or wishing to become pregnant
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Diabetes type 2 are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
CERITD (Centre d'Etudes et de Recherches pour l'Intensification du Traitement du Diabète),
Évry, 91058, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can six weeks of leg presses recharge aging muscles?
- Diabetes Care's hidden hurdle: can patients understand the advice?
- Can we predict kidney damage in young diabetics before it starts?
- Can music tame blood sugar and anxiety before surgery?
- Can a diabetes drug rev up muscle power?
- Electric pulse therapy in the gut: a new hope for type 2 diabetes?